A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults ≥ 18 Years With Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG

Trial Profile

A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults ≥ 18 Years With Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Dasatinib (Primary) ; Alemtuzumab; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Etoposide phosphate; Filgrastim; Fludarabine; Folinic acid; Folinic acid; Melphalan; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Pegfilgrastim; Tacrolimus; Tacrolimus; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 18 Nov 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top